The ARFGEF2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 near-haploid human cell line. This product provides a heterogeneous pool of cells harboring target-gene disruptions in ARFGEF2, enabling loss-of-function studies without clonal selection. The polyclonal format retains genetic diversity within the knockout background, facilitating robust phenotypic analysis of ARFGEF2-dependent processes.
HAP1 is an adherent, fibroblast-like cell line originating from the KBM-7 chronic myeloid leukemia line. Its near-haploid karyotype makes it exceptionally useful for genetic knockout studies, as a single targeting event can produce a functional null phenotype. HAP1 cells are extensively employed in haploid genetic screens and reverse genetic approaches, offering a simplified genomic context for investigating gene function in human disease-relevant pathways.
ARFGEF2, also known as BIG2, encodes a guanine nucleotide exchange factor for ADP-ribosylation factors (ARFs), specifically activating ARF1 and ARF3. It catalyzes GDP-to-GTP exchange to drive COPI coat assembly, Golgi-to-ER retrograde transport, and endosomal sorting. ARFGEF2 interacts with the coatomer complex, tubulin, and FKBP12, and is regulated by Golgi-localized kinases and brefeldin A. Downstream, ARF activation recruits COPI subunits to membranes, maintaining Golgi and endosomal organization. Key pathway components include ERGIC, GM130, and various Rab proteins.
In the HAP1 background, disruption of ARFGEF2 generates a valuable model for dissecting Golgi architecture and membrane trafficking. The near-haploid nature of HAP1 ensures that gene disruption leads to clear loss-of-function phenotypes, unmasking ARFGEF2??s roles in organelle integrity and protein secretion. This model is particularly relevant for studying periventricular nodular heterotopia, a brain malformation linked to ARFGEF2 mutations, enabling investigation of aberrant neuronal migration and trafficking defects.
Researchers can use this polyclonal knockout population to study Golgi organization via immunofluorescence microscopy with markers such as GM130, assess ARF1 activation through co-immunoprecipitation or effector pull-downs, and quantify secretion efficiency in trafficking assays. Western blotting for BIG2 and RT-qPCR for ARFGEF2 mRNA provide validation tools. The model supports mechanistic studies of COPI-dependent transport and endosomal dynamics. For additional information and technical support, please contact Ascent Research.
